Imugene Ltd
IMU
Company Profile
Business description
Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.
Contact
4-6 Bligh Street
Suite 12.01, Level 12
SydneyNSW2000
AUSSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
5
Stocks News & Analysis
stocks
ASX reporting season wrap: CBA, JB Hi-Fi, REA and more
A round up of notable stories and reactions as ASX earnings season gathers steam.
stocks
Market overreacts to soft guidance from ASX share
Shares undervalued after they plunge following results.
stocks
CBA earnings: The only thing that puzzles us is the share price
No surprises in fiscal 2025 earnings.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,149.10 | 46.00 | 0.51% |
| CAC 40 | 7,853.40 | 48.43 | 0.62% |
| DAX 40 | 24,354.45 | 168.86 | 0.70% |
| Dow JONES (US) | 44,922.27 | 463.66 | 1.04% |
| FTSE 100 | 9,172.37 | 7.14 | 0.08% |
| HKSE | 25,519.32 | 94.35 | -0.37% |
| NASDAQ | 21,713.14 | 31.24 | 0.14% |
| Nikkei 225 | 42,649.26 | 625.41 | -1.45% |
| NZX 50 Index | 12,834.08 | 67.54 | 0.53% |
| S&P 500 | 6,466.58 | 20.82 | 0.32% |
| S&P/ASX 200 | 8,873.80 | 46.70 | 0.53% |
| SSE Composite Index | 3,666.44 | 17.02 | -0.46% |